2022 spells change for EU pharmaceutical legislation
European Pharmaceutical Review
JUNE 24, 2022
Stakeholders in the EU often use the risk-adjusted Net Present Value (rNPV) investment model to determine whether to invest in a pharmaceutical product. The actual legislation will then have a certain implementation period and will be prospective, for the most part. Key areas of potential legislative change. About the author.
97 
Let's personalize your content